Takeda Invests $580M in AcuraStem's ALS Treatments, Forges License Agreement to Advance PIKFY

Monrovia, CA, September 25, 2023 (PRNewswire) -- AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced today that it has entered into a license agreement with Takeda to develop and commercialize AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Read full article here.